Pfizer, BioNTech start trial for third booster dose against new Covid-19 variants
The Phase 1/2/3 trial evaluates the safety and tolerability of a third dose of BNT162b2 and its effectiveness…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
26 Feb 21
The Phase 1/2/3 trial evaluates the safety and tolerability of a third dose of BNT162b2 and its effectiveness…
23 Feb 21
The Phase 2 trial is designed to determine the appropriate antigen dosage for Phase 3 evaluation of their…
19 Feb 21
The Phase 2/3 study will enrol healthy pregnant women, aged 18 years and older, and vaccinate them during…
04 Feb 21
The vaccine demonstrated 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase 3…
01 Feb 21
The vaccine showed 72% effectiveness in the US and an overall 66% effectiveness in preventing Covid-19 after 28…
28 Dec 20
Covaxx, is currently conducting phase 1 clinical trial for the vaccine candidate
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
23 Dec 20
Treatment using tezepelumab did not meet the primary endpoint of statistically significant reduction in the daily OCS dose,…
09 Dec 20
In the interim analysis, the vaccine showed efficacy in preventing Covid-19, with no severe cases or hospitalisations after…
08 Dec 20
INO-4800 is an advanced prophylactic DNA vaccine candidate, designed to work against the activity of SARS-CoV-2, the virus…
19 Nov 20
The primary efficacy analysis in 170 confirmed cases of Covid-19 showed that BNT162b2 is 95% effective in preventing…